Vir Biotechnology (VIR) Cost of Revenue (2021 - 2025)

Vir Biotechnology's Cost of Revenue history runs 5 years deep, the most recent figure standing at $11000.0 for Q2 2025.

• In Q2 2025, Cost of Revenue fell 78.85% year-over-year to $11000.0; the TTM figure through Jun 2025 stood at $745000.0 (down 21.33% YoY), while the FY2025 annual figure was $26000.0, down 96.92% from the prior year.
• Cost of Revenue came in at $11000.0 for Q2 2025 at Vir Biotechnology, down from $684000.0 in the prior quarter.
• In the past five years, Cost of Revenue ranged from a high of $90.1 million in Q1 2022 to a low of $11000.0 in Q2 2025.
• A 5-year average of $13.5 million and a median of $971000.0 in 2021 frame the typical range for Cost of Revenue.
• Across the five-year window, Cost of Revenue jumped 2340.65% in 2022 and sank 99.92% in 2023, its largest moves.
• Vir Biotechnology's Cost of Revenue stood at $56.9 million in 2021, then plunged by 89.46% to $6.0 million in 2022, then sank by 86.69% to $798000.0 in 2023, then retreated by 14.29% to $684000.0 in 2024, then sank by 98.39% to $11000.0 in 2025.
• According to Business Quant data, Cost of Revenue over the past three periods registered $11000.0, $684000.0, and $50000.0 for Q2 2025, Q4 2024, and Q3 2024 respectively.

Peer Comparison